Cymbalta
Cymbalta
$10,000.00
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain.
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain. The drug is also marketed for the treatment of women with moderate to severe stress urinary incontinence in Europe under the brand name Yentreve.
Cymbalta was formerly marketed by Boehringer Ingelheim in a number of European countries under the brand name Xeristar, although Eli Lilly has since reacquired exclusive rights to develop and market duloxetine. In Japan – where Cymbalta was not launched until April 2010 – the drug is jointly marketed by Shionogi and Eli Lilly for the treatment of depression and depressive symptoms.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Cymbalta : Depression
16 Cymbalta : Neuropathic pain
LIST OF FIGURES
11 Figure 1: Datamonitor Healthcare’s drug assessment summary of Cymbalta for depression
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cymbalta for depression
14 Figure 3: Cymbalta sales for depression across the US, Japan, and five major EU markets, by country, 2017–26
18 Figure 4: Cymbalta for neuropathic pain – SWOT analysis
19 Figure 5: Datamonitor Healthcare’s drug assessment summary of Cymbalta for neuropathic pain
20 Figure 6: Datamonitor Healthcare’s drug assessment summary of Cymbalta for neuropathic pain
22 Figure 7: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Cymbalta drug profile
6 Table 2: Approval history of Cymbalta for depression in the US, Japan, and five major EU markets
7 Table 3: Late-phase trials of Cymbalta for depression
10 Table 4: Cymbalta ongoing Phase III trials in depression
10 Table 5: Cymbalta for depression – SWOT analysis
16 Table 6: Cymbalta drug profile
17 Table 7: Cymbalta Phase III data in neuropathic pain syndromes
23 Table 8: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the